Absci announces first participants dosed in phase 1 clinical trial of abs-101, a potential best-in-class anti-tl1a antibody for the treatment of inflammatory bowel disease

Absci becomes clinical stage company with abs-101, first ai-designed biologic for ibd, beginning phase 1 trial preclinical data for abs-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over first-generation anti-tl1as interim data anticipated in the second half of 2025 vancouver, wash., may 13, 2025 (globe newswire) -- absci corporation (nasdaq: absi) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative ai, today announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled phase 1 study evaluating abs-101, an investigational anti-tl1a antibody engineered with absci's generative ai platform.
ABSI Ratings Summary
ABSI Quant Ranking